Are you looking for expert advice...

Since the legalisation of cannabis-based medicinal products (CBPMs) in the UK in November 2018, around 40,000 patients have received these treatments, with numbers steadily increasing. There are currently 40 clinics and about 140 prescribers operating within the private sector.

However, the adoption of these medicines within the NHS has been slow, and there are no compulsory training requirements for prescribers. This has led to significant variations in clinical practice.

To address these challenges, the Medical Cannabis Clinicians Society (MCCS) has developed a Good Practice Guide. This guide aims to support prescribers and ensure patients can safely access these valuable medicines. While it is tailored primarily for clinics that focus on prescribing cannabis, the fundamental principles are relevant to a broader range of medical settings.

The MCCS hopes this guide will be adopted widely, pleading to practices that benefit patients and improve the overall quality of the medical cannabis industry.  This effort highlights our dedication to raising standards and supporting prescribers with practical, applicable guidelines and support.

Download the Good Practice Guide >>>

 

You can access all our public publications – including this recently published Good Practice Guide – on our website.

Not yet a member? Join the Society.

The UKMCCS Annual General Meeting (AGM) is around the corner, and we’re looking forward to bringing members together to review our achievements and discuss future developments. Members are invited to join us on 7 November, from 2 PM to 4 PM to take part.

Members have two ways to attend:

  1. In-Person – We have 20 spaces available at our London venue, so secure your place soon by emailing [email protected].
  2. Online via Teams – For those preferring virtual attendance, we’ll be streaming the AGM live. Email us at the same address for the Teams link.

For members who can’t attend, minutes will be shared afterward to keep everyone informed.

AGM Details

???? Date: 7 November
???? Time: 2 PM to 4 PM
???? Location: Farringdon Road, London, EC1M 3HE

To register, please email [email protected]. We look forward to your participation in making this a successful AGM.

Together with the Cannabis Industry Council and Drug Science, the Medical Cannabis Clinicians Society is pleased to announce the first-ever Cannabis Industry Awards. 

The event is being held during Medical Cannabis Awareness Week, making it a fitting occasion to celebrate excellence in the UK cannabis sector.

The Cannabis Industry Awards is set to be a key event for the UK cannabis community. It will bring together professionals from across the industry, including CEOs, founders, doctors, scientists, and other leading figures. Guests will enjoy a three-course meal, with entertainment provided by a comedian and table magicians. Following the dinner, there will be an after-party at a nearby venue, offering further opportunities to connect and celebrate.

About the Awards

The evening will feature two awards: the Social Impact Award and the Contribution to Science Award. These awards are designed to recognise individuals who have made notable contributions to the cannabis industry. 

Nominations are open from 2 September to 1 October, with a public vote from 4 to 25 October to decide the winners, reflecting the views and values of both industry insiders and the wider community.

Dr Leon Barron, Chair of the Medical Cannabis Clinicians Society, said:

“The Cannabis Industry Awards Dinner is a chance for us to come together and celebrate the progress we’ve made in the UK cannabis sector, particularly in improving access for patients and supporting clinicians in prescribing since 2018. These awards recognise the hard work and dedication of individuals who are helping to shape the future of the industry in two key areas. I’m looking forward to what will undoubtedly be a memorable evening.”

Buy your tickets 

To purchase your tickets, visit the official Eventbrite page. 

Book Your Tickets

 

Sponsorship Opportunities Available

While the Contribution to Science Award has been sponsored by Gowling WLG, there is still an opportunity for an organisation to sponsor the Social Impact Award. This sponsorship offers a chance to show support for social responsibility within the cannabis industry.

For organisations interested in sponsoring the Social Impact Award, please contact Sam Cannon at [email protected] for more information.

As part of our commitment to keeping healthcare professionals at the forefront of medical cannabis knowledge, we are pleased to give you access to a detailed webinar and a new research paper by Dr. Stefan Broselid, Scientific Lead at the Medical Cannabis Clinicians’ Society.

Webinar Recording

This webinar explores the endocannabinoidome (eCBome) — an advanced version of the endocannabinoid system. This session, which took place on 11 June 2024, provides a comprehensive understanding of how this complex system affects various body processes and how you can target it effectively with cannabis-based treatments. Member’s can access this recording via the Member’s Area. 

Research Paper

Dr. Broselid’s linked paper, “The Endocannabinoidome: A Pivotal Physiological Regulator and Therapeutic Target – Implications for Medical Education and Personalized Medicine”, goes beyond theory to discuss practical implications for clinical practice, especially in prescribing and managing cannabis-based medicinal products (CBMPs).

Download the paper>>>

For more information, questions, or to discuss the content, please do not hesitate to get in touch wit the Society by emailing [email protected].

The Medical Cannabis Clinicians Society is pleased to announce that the Primary Care Cannabis Network (PCCN) has become a part of our Society. This is an important step forward in our mission to normalise the conversation around medical cannabis and increase clinician knowledge of this treatment in the UK. We look forward to working together towards our shared goals.

Continuing and developing the work of the PCCN

The PCCN was set up in November 2019 by GP Dr Leon Barron to provide GP education in medical cannabis. Striving to increase knowledge and open dialogue, the PCCN worked to create an environment of balance and understanding around this rapidly developing field of medicine within primary healthcare. Its goals – to eradicate stigma associated with medical cannabis and improve the primary care sector’s comfort in discussing treatment options with patients – are aligned with the vision and mission of the Medical Cannabis Clinicians Society.

In order to better meet our joint goals, the Society has welcomed the PCCN and its members into the Society. By educating and supporting general practitioners (GPs) with current guidelines and evidence-based medicine, the Society can ensure that primary care providers have access to the most up to date resources to enable informed conversations with patients.

The integration of the PCCN with the Society will give every clinician the opportunity to be part of the biggest network of healthcare professionals dedicated to expanding access to medical cannabis treatment through education and support.

The role of GPs in the widespread understanding of medical cannabis as a treatment option

As the frontline in patient access to specialist clinicians, GPs have a crucial role to play in the understanding and acceptance of medical cannabis as a treatment option for patients in the UK. 

Learn more

Why should GPs be open minded about talking to patients who are self medicating with cannabis in the UK?

GPs should be open minded about talking to patients who are self medicating with cannabis because it is becoming increasingly accepted in the UK as an effective means of treating various health conditions. 

Learn more

Can GPs prescribe medical cannabis in the UK?

Currently in the UK, prescriptions for unlicensed cannabis based medicines can only be initiated by a doctor on the GMC specialist register (consultants) and must be initiated on a private prescription. Unlike most other countries across the globe where medical cannabis is legal, current UK legislation does not permit GPs to initiate treatment for medical cannabis. However, GPs can play an important role in the management and monitoring of their patient’s use of medical cannabis, and a GP can prescribe under shared care arrangements under the direction of a specialist.

Learn more

Comprehensive education and support for GPs through the Society

The Medical Cannabis Clinicians Society is an important resource for clinicians in regards to the education, peer support, and guidance related to medical cannabis use. Through the integration of the PCCN, a new sub group will be formed to provide GP focussed education and peer support.

All the resources from the PCCN will be available via the Society website. This includes access to evidence-based information and practical resources.

In addition, the Society will provide opportunities for GPs to network with peers and discuss the opportunities for GP prescribing of medical cannabis within a supportive environment.

PCCN Members – Join the Society today

Joining the Society provides GPs with access to training and resources from leading experts in the field. In addition, members can benefit from ongoing support and guidance on prescribing medical cannabis, as well as staying up to date with changing regulations. The Society also organises regular events for members to exchange ideas and discuss best practices in medical cannabis.

As members, GPs can ensure they are up to date with the latest evidence-based information in this field and help their patients access effective medical cannabis treatments.

Current members of the PCCN are invited to become members of the Society at no cost for the first year of membership.

Join now

The Medical Cannabis Clinicians Society’s Guide to CBD has been newly updated for 2021.

The expanded guidance supports doctors and clinicians who wish to understand how CBD works, what a good CBD product looks like, and how better to support patients who are taking CBD.

Version 2 of the guidance, written by the Society’s Dr Leon Barron, Vice-Chair Dr Dani Gordon and Chair, Prof Mike Barnes, has been supported by expert researchers at Bud & Tender.

Download the guide here.

On Thursday 21st October, join The Medical Cannabis Clinicians Society and Bud & Tender as we explore what clinicians need to know about CBD. A fantastic live overview of the guide, this webinar will provide an overview of CBD for clinicians, including Endocannabinoid tone, modes of action and therapeutic effects, pharmacodynamics, different types of CBD oil available in the UK, controlled cannabinoids, Certificates of Analysis (COA’s) and dosing. We also summarise the current legal status of CBD in the UK.

BOOK NOW

 

 

Below is the text of an open letter which has been sent from the Medical Cannabis Clinicians Society to The Secretary of State for Health, Sajid Javid.

Members of The Medical Cannabis Clinicians Society have access to further information including prescribing guidelines, a secure online support network and events – covering what is needed to become a specialist prescriber of medical cannabis.

If you are a Paediatric Consultant of any discipline and would like to consider prescribing, we will provide free CPD-accredited training (online & face to face) and ongoing support and mentoring to you. Find out more about joining us. 

Open Letter, sent 4 October 2021

Dear Secretary of State for Health and Social Care,

The Medical Cannabis Clinicians Society (MCCS) was created in 2018 to support and educate clinicians who wish to prescribe medicinal cannabis in the UK. Today we write because of our considerable concern about the current situation regarding children with drug-resistant epilepsy who are denied NHS prescriptions for a medicine that has been shown to be life transforming for them.

There is now overwhelming evidence of the efficacy of medicinal cannabis for these children. A recent paper by Drug Science showed that there is a 96% chance of a child significantly improving after prescription of full spectrum cannabis. This is a remarkable statistic given that these children will have been resistant to all licensed anti-convulsant drugs, often suffering from hundreds of seizures weekly and experiencing a very poor quality of life combined with a risk of death. Although this was a relatively small UK study, similar outcomes have been demonstrated in many other larger international studies in children with drug-resistant epilepsy. Also, in more established medical cannabis markets such as Canada, US and Israel, there are now thousands of children with drug-resistant epilepsy who are being prescribed full spectrum products after licenced medications have failed to work, often with dramatic improvements in seizure control and quality of life.  Treating these children with conventional anti-epileptic medicines and other techniques is costing the NHS millions of pounds each year to care for them. However, when using medicinal cannabis products, many of them have remained at home and have had huge improvements in their seizure control and their cognitive development with consequential significant savings to the NHS in terms of pharmaceutical and hospital costs.

The British Paediatric Neurology Association (BPNA) declares itself to be the professional medical body for paediatric neurologists.  Apart from a specific brand (which is not full spectrum) in very limited circumstances that has been through the conventional licencing system, the BPNA appears to be very much opposed to the prescription of medical cannabis products. From what we understand, they appear to want to see more evidence about safety and efficacy and are concerned that these ‘full spectrum’ products are unlicenced.

Both of these points are hard to understand.  By more evidence, we presume they mean evidence generated from Randomised Control Trials (RCTs).  However, full spectrum medical cannabis has many active ingredients and is therefore, by definition, not well suited to such trials. And they seem reluctant ‘in extremis’ to accept the enormous volume of real world and observational evidence. And the fact that a medicine is unlicenced is not a bar to its prescription. Unlicenced medicines are routinely prescribed for a range of conditions.

Our concern is that what appears to be a deeply entrenched and dogmatic position on this subject from the BPNA is effectively denying sick children access to an efficacious and safe medicine that may well reduce or even stop their seizures and immeasurably improve their quality of life and reduce their chance of death.  It is deterring private prescriptions and is playing a part in the almost total block on NHS prescriptions.  This block in turn is forcing many very vulnerable families to have to fundraise thousands of pounds a month to source the medicine privately.

The BPNA’s current guidance states that you must be a paediatric neurologist to prescribe.  But this is their view.  It is not based on law and as we show here is not supported by national guidance.

It is our understanding that such is their strength of feeling on this matter, that the BPNA have referred one doctor who was prescribing such medicines to the General Medical Council (GMC) on the basis that he was a paediatric rheumatologist rather than a paediatric neurologist. Thankfully after careful review this case has now been dropped.  The GMC found no fault and no further action will be taken.  With the permission of the doctor concerned we highlight the following quote from the contribution of the GMC’s own independent medical expert.

“Dr X appears to have provided adequate care to the families who consulted him, with evidence of benefit, and no evidence of harm. The BPNA position that only Paediatric Neurologists should initiate treatment is not supported by other national guidance, and probably not in the best interests of children, as it may impede debate and research into the appropriate use of Cannibidiols (sic) in refractory epilepsy”.

Currently, there are just two paediatric neurologists prescribing for children and one of them is retiring in October.  Soon, there will be only one prescriber for over 100 children currently being administered these medicines and many thousands more who might benefit. This is simply unacceptable and puts the children who have prescriptions at real risk from rebound seizures, if they lose their prescribers.

We are calling on members of both the BPNA and the wider paediatric community to:

  1. Question the current position of the BPNA and to consider real world evidence and to treat individual patients on a case-by-case basis.
  2. Take into account the recently clarified NICE guidance which now recognise that cannabis prescription is reasonable if all else has failed and a child has responded to the medicine – “Patients in this population can be prescribed cannabis-based medicinal products if the healthcare professional considers that that would be appropriate on a balance of benefit and risk, and in consultation with the patient, and their families and carers or guardian…. There is no recommendation against the use of cannabis-based medicinal products”.
  3. When clinically appropriate, advocate for and where possible deliver, the prescription of full spectrum medicines on the NHS.
  4. Avail themselves of the offer of the MCCS to train free of charge and mentor any paediatrician who wishes to prescribe. The MCCS have set up a Resistant Epilepsy Cannabis Assessment Panel (RECAP) to assess individual cases. This panel has national cannabis experts and international paediatric neurologists including Dr. Carter Snead, Dr.Evan Lewis and Dr. Richard Huntsman. Contact can be made by emailing [email protected].

We ask that you, as the Secretary of State for Health & Social Care:

  1. Support our calls to the medical paediatric community as above.
  2. Work with the NHS and the wider medical community, including the MCCS to ensure that the barriers currently blocking NHS prescriptions to the cohort of paediatric epilepsy patients are broken down.

Yours,

Medical Cannabis Clinicians Society – Executive Committee and Members
Professor Michael Barnes (Chair) Consultant Neurologist & Consultant in Rehabilitation Medicine
Dr Evan Lewis Paediatric Neurologist (Canada)
Dr Sunil Arora Pain Consultant and Anaesthetist
Dr Danielle Gordon GP
Dr Leon Barron GP
Dr Niraj Singh Consultant Psychiatrist
Dr Rebecca Moore Consultant Psychiatrist
Dr Elizabeth Iveson Consultant Geriatrician
Dr Eliezar Okirie Consultant in Neurological Rehabilitation
Dr Beverley Fairclough Consultant Psychiatrist
Dr Nathan Hasson Consultant Paediatric Rheumatologist
Dr Luisa Searle Consultant Psychiatrist
Dr A Suleman GP
Dr Adam Bentley GP
Dr Brian Birch Consultant Urologist
Dr Harrison Offiong GP
Dr Tahzid Ahsan Consultant Psychiatrist
Dr Osama Hammer Consultant Psychiatrist
Dr Jake Timothy Consultant Neurosurgeon and Spinal Surgeon
Dr Ron Velthuis GP (the Netherlands)
Dr Sandeep Bolia GP
Dr Gurprit Atwal Consultant Histopathologist and Medical Examiner
Dr Julia Piper GP
Dr Prabha Moorti Consultant Psychiatrist
Dr Jen Anderson GP (Canada)
Dr Iqbal Mohiuddin Consultant Psychiatrist
Dr Andrew Sanger Bowen GP
Dr Elaine Tickle GP
Dr A J Wallis GP
Dr David Howells Consultant Psychiatrist
Dr Vimal Sivasanker Consultant Psychiatrist
Dr Anup Mathew Consultant Psychiatrist
Dr Caroline Bealing GP
Dr Maria Kallikourdi Consultant Psychiatrist
Dr Andrew Bradford Consultant in Neurological Rehabilitation
Dr Mark Smith GP
Dr Sharon Hadley GP
Dr Robert Greig Consultant in Emergency Medicine
Dr Naheem Bashir GP
Dr Anthony Ordman Consultant in Pain Medicine
Dr David Tang Consultant in Emergency Medicine
Dr Charlotte Cocks GP
Dr Neil Wright GP
Dr Graham Sanderson GP
Dr Sudha Balakrishnan Consultant in Rehabilitation Medicine
Dr Lauren Kelly Scientific Director, Canadian Childhood Cannabinoid Clinical Trials
Dr Tahira Ellahi Consultant Psychiatrist
Dr Simmi Sachdeva-Mohan Consultant Psychiatrist

 

Medical cannabis training for UK doctorsExclusively for members of The Medical Cannabis Clinicians Society, every two months doctors and medical students have the opportunity to attend a half-day, live and interactive Zoom training session with Professor Mike Barnes.

Medical Cannabis Explained: everything you need to know to become a confident prescriber

The three-hour interactive medical cannabis training session for UK doctors covers:

Through the Society, members can already access training programmes which can be completed at your own pace, as well as a range of resources which cover the process of becoming a prescriber, products and frequently asked questions. With the launch of live training sessions in 2021, for the first time, members can book a live training session, sharing questions in advance.

To book your place, please visit Eventbrite and select your chosen date. Please add your full name and email address.

If you are not a member of the Society but wish to access the training, you can join the Society here. When your membership is confirmed, you will be able to book your place. Your booking will be cancelled and refunded if you are not a Society member.

Medical Cannabis Awareness Week 2020

During Medical Cannabis Awareness Week 2020, 1 – 8 November, we are supporting PLEA’s call for patients, doctors, colleagues from across the sector, friends and supporters to fight for fair access to medical cannabis, using the hashtag #MCAW2020.

During Medical Cannabis Awareness Week, PLEA is:

It’s time to end the inequality and ensure everyone who needs it has the opportunity to benefit from medical cannabis treatment. Medical Cannabis Awareness Week will take place during the first week of November every year. Visit www.medicalcannabisawarenessweek.org.uk for ideas about how you can get involved.

Take part

Society Chair Prof Mike Barnes and Dr Elie Okirie are hosting a special webinar for clinicians interested in supporting patients with medical cannabis treatments.

Register here – healthcare professionals only, please: https://zoom.us/webinar/register/WN_5rjqG_g9Qs2WquEMQNMX9Q

 

John Ellis lives with Progressive Mylopathy of uncertain cause. Here, he tells his story.

A decade of declining health

In early 2002 whilst working as a broadband technician, I began to notice loss of memory and a change in smell and taste. After a few months of this problem worsening I was put-on long-term health support with the company, as my work required quick and accurate recall a lot of technical information.

After undergoing private cognitive therapy without much success in outcomes, I spent the next few years with my wife supporting our local community, creating a community group working with the police and other official bodies. In later years we set up a community garden with the help of other locals. It was during the latter years that my illness worsened and by 2010 cognitive loss, general pain and inability to mobilise myself properly had started to set in.

By 2011/2012 my condition had become progressively worse, to the point where I needed assistance to walk. I had already visited my doctor several times with different doctors viewing my deterioration in several ways. One even put all my issues down to my use of cannabis for pain management, even though I explained why I thought it worked better than non-steroidal anti-inflammatory drugs. Eventually, I engaged with a doctor that saw me as a patient first. He immediately arranged for an appointment with Walton Hospital and a neurologist.

Reaching a diagnosis

After undergoing a raft of physical tests including an MRI, my first initial diagnosis was for Primary Progressive Multiple Sclerosis. This was ruled out and changed to Progressive Myelopathy of uncertain cause.

The MRI showed lesions in the upper right pons – part of the brainstem – and many white matter lesions, whilst somatosensory test showed I had lost the somatosensory pathways back to my central cortex. This means the electrical signals travel out from my brain but do not travel back to the central cortex. The blood test results showed very low copper/Ceruloplasmin levels and lactic acid levels well above normal.

The symptoms of the copper deficiency are wide ranging, affecting everything from cellular respiration to enzyme production involved in neurological messenger breakdown, normally only seen in people who have had bariatric surgery presenting with a loss of gait and lower body functions and muscle spasms. Normally, replacing copper fixes the problem, but for me, the copper levels stayed low and fell even further over the years.

Chronic, long-term pain

I’m in almost constant pain. It is not what I would describe as normal pain – more of a sensory overload/emptiness, with smooth objects I hold feeling like they are made from a million tiny needles to hot wires being pulled through muscle and skin and numbness to the touch in my legs.

Exhaustion and fatigue are common problems with my illness, aggravated greatly with any form of exercise or rise/fall in external temperatures. Some days my body temperature can stay at 35.6 degrees and can stay that way for days. At my worst, a flare up can take a month or two to recover from.

I have trailed several prescription drugs over the years to help with pain management.

My pain specialist said that there is no mechanical intervention that can help – such as gabapentin and amitriptyline, both of which amplified the discomfort. Lamotrigine caused horrendous locked-in dreams and night terrors. I was taken off Lamotrigine after three weeks due to possible psychosis through lack of sleep, as I became terrified to sleep.

Since then I have partly stabilised on sodium valproate, baclofen, solifenacin succinate, copper supplement and currently 0.3 grams of cannabis at bedtime which I limit due to costs.

My medical cannabis journey

I have always been aware of cannabis, using it both recreationally when I was younger and now for medical use. I’m a very long way of gaining a prescription however, as the current costs are prohibitive to me. So, I rely on black market cannabis.

My Consultant and Pain Management Specialist have both been supportive on my medical notes have listed ‘up to a gram and a half per day’ under ‘current medication’, even though this is not via a prescription as it is unaffordable at those quantities and is not yet available on the NHS.

When I was first diagnosed, I was offered a month trial of Sativex. I turned this down as I had already enquired with my CCG about prescription costs – which they had already refused on costs alone. I was however lucky enough to try Sativex several years later during a visit to Parliament regarding the prescription of cannabis products.

Sativex turned out to be very effective for most of my symptoms, reducing my tiredness and fatigue as well as the pain and spasticity in my legs. I have done the majority of my own research over the years on how it effects my illness, even surprising some of my medical providers with knowledge on how cannabinoids interact with parts of my illnesses.

The future of medical cannabis prescriptions

I believe it is vital for everyone that cannabis prescriptions and cannabis-based products are brought onto the NHS, in part because of the unreliability of black market cannabis and more importantly the general health of patients.

Like many ordinary people, I don’t have the income to be treated via private clinics with a basic prescription and costs equating to nearly a third of our income per month.

All we are asking for is a replication of the Dutch Bedrocan range of plants and oils which will suit most patient’s needs.

 

John Ellis is a member of the Society’s Patient Committee.